Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02475265 · ClinicalTrials.gov registry record · Phase 2

Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa

A Phase 2 study, sponsored by Massachusetts General Hospital.

Completed
Registry status
Phase 2
Development phase
11
Enrollment target

NCT02475265: Completed Phase 2 study, sponsored by Massachusetts General Hospital.

NCT02475265 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02475265, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
Phase 2
Development phase
11 participants
Enrollment target

Study Summary

Decreased bone strength is a common and serious medical problem present in many women with anorexia nervosa. Women with decreased bone strength are more likely to suffer broken bones than women with normal bone strength. This study will investigate whether the use of transdermal estrogen can improve bone mineral density (BMD) and bone microarchitecture in women with anorexia nervosa anorexia nervosa when used for 6 months.

Interventions

  • DRUG estradiol 0.045 mg/levonorgestrel 0.015mg

Trial Details

FieldValue
Enrollment Target 11 participants
Start Date 2015-07
Est. Completion 2018-07-30
Phase Phase 2

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT02475265

The ClinicalTrials.gov registry entry for NCT02475265 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which estradiol 0.045 mg/levonorgestrel 0.015mg is the first listed.

NCT02475265 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02475265 about?

NCT02475265 is a clinical study titled "Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa". Decreased bone strength is a common and serious medical problem present in many women with anorexia nervosa. Women with decreased bone strength are more likely to suffer broken bones than women with normal bone strength. This study will investigate whether the use of transdermal estrogen can improv...

What is the current status of trial NCT02475265?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2015-07. Estimated completion is 2018-07-30.

What interventions are being tested in trial NCT02475265?

The interventions under investigation include: estradiol 0.045 mg/levonorgestrel 0.015mg (DRUG).

Who is sponsoring clinical trial NCT02475265?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.